Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects

被引:16
作者
Davignon, J [1 ]
机构
[1] Clin Res Inst Montreal, Hyperlipidemia & Atherosclerosis Res Grp, Montreal, PQ H2W 1R7, Canada
关键词
D O I
10.1016/S0002-9149(98)00253-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:17F / 23F
页数:7
相关论文
共 110 条
[1]  
ADELMAN SJ, 1995, ATHEROSCLEROSIS, V10, P316
[2]   GEMFIBROZIL - INTERACTION WITH GLYBURIDE [J].
AHMAD, S .
SOUTHERN MEDICAL JOURNAL, 1991, 84 (01) :102-102
[3]   INHIBITION OF IL-1-BETA EXPRESSION IN THP-1 CELLS BY PROBUCOL AND TOCOPHEROL [J].
AKESON, AL ;
WOODS, CW ;
MOSHER, LB ;
THOMAS, CE ;
JACKSON, RL .
ATHEROSCLEROSIS, 1991, 86 (2-3) :261-270
[4]   THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
YEUNG, AC ;
FREI, B ;
SELWYN, AP ;
GANZ, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493
[5]  
ARAD Y, 1990, J LIPID RES, V31, P567
[6]   INSULIN ACTION AND GLUCOSE-METABOLISM ARE IMPROVED BY GEMFIBROZIL TREATMENT IN HYPERTRIGLYCERIDEMIC PATIENTS [J].
AVOGARO, A ;
BELTRAMELLO, P ;
BONANOME, A ;
BIFFANTI, S ;
MARIN, R ;
ZAMBON, S ;
CONFORTIN, L ;
MANZATO, E ;
CREPALDI, G ;
TIENGO, A .
ATHEROSCLEROSIS, 1995, 113 (01) :117-124
[7]  
BAKER SG, 1982, S AFR MED J, V62, P7
[8]   Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia [J].
BakkerArkema, RG ;
Davidson, MH ;
Goldstein, RJ ;
Davignon, J ;
Isaacsohn, JL ;
Weiss, SR ;
Keilson, LM ;
Brown, WV ;
Miller, VT ;
Shurzinske, LJ ;
Black, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02) :128-133
[9]   SIMVASTATIN-SODIUM DELAYS CELL-DEATH OF ANOXIC CARDIOMYOCYTES BY INHIBITION OF THE NA+/CA2+ EXCHANGER [J].
BASTIAANSE, EML ;
ATSMA, DE ;
KUIJPERS, MMC ;
VANDERLAARSE, A .
FEBS LETTERS, 1994, 343 (02) :151-154
[10]  
BIANCHI A, 1993, THROMB HAEMOSTASIS, V70, P241